Radius Health, Inc., has announced it has completed a new equity financing of $43 million.
Radius, based in a Cambridge, Mass., is a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women’s health conditions.
The financing was led by F2 Biosciences III, L.P. F2 is a family of life science funds established by Morana Jovan-Embiricos
Participation also came from the following existing investors: Biotech Growth N.V., MPM Capital, Brookside Capital, MPM Bio IV NVS Strategic Fund and BB Biotech Ventures.
Radius intends to use the funding to support its clinical development programs for BA058, the company’s anabolic, bone-building compound developed for the treatment of patients with osteoporosis at high risk of fracture.